SECURITIES
      AND EXCHANGE COMMISSION


WASHINGTON,
      D.C. 20549





FORM
      10-QSB





x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF
      1934





For
      the
      quarterly period ended June 30, 2007





o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF
      1934





For
      the
      transition period from _______________ to _________________





Commission
      file number: 000-32253





HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC.


(Name
      of
      Small Business Issuer as specific in its Charter)





Nevada
            
            87-0650264(State
                or Other Jurisdiction of Incorporation or Organization)
            
            (I.R.S.
                Employer Identification No.)


16B/F
      Ruixin Road Bldg. No. 25 Gaoxin Road


Xi
      An
      710075 Shaanxi Province, China





(Address
      of Principal Executive Offices Including Zip Code)





Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days. x Yes o No





The
      number of shares outstanding of the registrant's common equity as of August
      13,
      2007, was 18,466,169 shares
      of common stock, par value $0.018.





Transitional
      Small Business Disclosure Format (Check one): o Yes x No










**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC.**


**AND
      SUBSIDIARIES**





**CONTENTS**





HUIFENG
                BIO-PHARMACEUTICAL TECHNOLOGY, INC.AND
                SUBSIDIARIESCONTENTS




**Pages**PART
                I. FINANCIAL INFORMATION
            
            1Item
                I. Financial Statements
            
            1Unaudited
                Condensed Consolidated Balance Sheet as of June 30, 2007
            
            1Unaudited
                Condensed Consolidated Statements of Operations and Comprehensive
                Income
                (Loss) for the three and six months ended June 30, 2007 and
                2006
            
            2Unaudited
                Condensed Consolidated Statements of Cash Flows for the six months
                ended
                June 30, 2007 and 2006
            
            3Notes
                to Unaudited Condensed Consolidated Financial Statements as of June
                30,
                2007
            
            4
                -
                7Item
                2. Management's Discussion and Analysis or Plan of
                Operation
            
            8-11Item
                3. Controls and Procedures
            
            11PART
                II. OTHER INFORMATION
            
            12Item
                1. Legal Proceedings
            
            12Item
                2. Unregistered Sales of Equity Securities and Use of
                Proceeds
            
            12Item
                3. Defaults Upon Series Securities
            
            12Item
                4. Submission of Matters to a Vote of Security Holders
            
            12Item
                5. Other Information
            
            12Item
                6. Exhibits and Reports on Form 8-K
            
            12SIGNATURES
            
            13











**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC**


**AND
      SUBSIDIARIES**


**UNAUDITED
      CONDENSED CONSOLIDATED BALANCE SHEET**


**AS
      OF JUNE 30, 2007**





**ASSETS****CURRENT
                ASSETS**Cash
                and cash equivalents
            
            $
            726,431Accounts
                receivable, net of allowances
            
            
            1,272,038Inventories,
                net
            
            
            1,804,568Notes
                receivable
            
            
            196,726Other
                assets
            
            
            413,815Total
                Current Assets
            
            
            4,413,578**PROPERTY
                AND EQUIPMENT, NET**
            
            
            3,513,860**LAND
                USE RIGHTS, NET**
            
            
            138,026**TOTAL
                ASSETS**
            
            $
            8,065,464**LIABILITIES
                AND STOCKHOLDERS' EQUITY****CURRENT
                LIABILITIES**Accounts
                payable
            
            $
            55,652Other
                payables and accrued expenses
            
            
            233,590Notes
                payables
            
            
            314,762Income
                tax and other tax payables
            
            
            253,531Total
                Current Liabilities
            
            
            857,535**COMMITMENTS
                AND CONTINGENCIES**
            
            
            -**MINORITY
                INTEREST**
            
            
            434,803**STOCKHOLDERS'
                EQUITY**Preferred
                stock, ($0.001 par value, 5,000,000 shares
                authorized,non
                issued and outstanding)
            
            
            -Common
                stock, ($0.018 par value, 100,000,000 shares authorized,18,466,169
                shares issued and outstanding as of June
                30, 2007)
            
            
            332,388Additional
                paid-in capital
            
            
            8,020,066Retained
                earnings (deficit)Unappropriated
            
            
            (2,119,224
            )Appropriated
            
            
            82,925Accumulated
                other comprehensive income
            
            
            456,971Total
                Stockholders' Equity
            
            
            6,773,126**TOTAL
                LIABILITIES AND STOCKHOLDERS' EQUITY**
            
            $
            8,065,464




The
      accompanying notes are an integral part of these financial
      statements




1




**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC**


**AND
      SUBSIDIARIES**


**UNAUDITED
      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**


**AND
      COMPREHENSIVE INCOME (LOSS)**





For
                the Three
            
            For
                the Three
            
            For
                the Six
            
            For
                the SixMonths
                Ended
            
            Months
                Ended
            
            Months
                Ended
            
            Months
                EndedJune
                30, 2007
            
            June
                30, 2006
            
            June
                30, 2007
            
            June
                30, 2006**NET
                SALES**
            
            $
            1,610,478
            
            $
            459,248
            
            $
            3,008,147
            
            $
            1,562,695**COST
                OF SALES**
            
            
            (1,042,071
            )
            
            (357,841
            )
            
            (2,031,889
            )
            
            (1,291,551
            )**GROSS
                PROFIT**
            
            
            568,407
            
            
            101,407
            
            
            976,258
            
            
            271,144**OPERATING
                EXPENSES**Selling
                expenses and distribution expenses
            
            
            24,652
            
            
            49,814
            
            
            43,696
            
            
            84,445General
                and administrative expenses
            
            
            93,763
            
            
            76,185
            
            
            134,760
            
            
            110,119Depreciation
                and amortization
            
            
            11,983
            
            
            10,787
            
            
            23,818
            
            
            22,981Total
                Operating Expenses
            
            
            130,398
            
            
            136,786
            
            
            202,274
            
            
            217,545**INCOME
                (LOSS) FROM OPERATIONS**
            
            
            438,009
            
            
            (35,379
            )
            
            773,984
            
            
            53,599**OTHER
                INCOME (EXPENSE)**Interest
                income
            
            
            7,986
            
            
            12,787
            
            
            13,867
            
            
            25,901Interest
                expense
            
            
            (8,371
            )
            
            (26
            )
            
            (17,759
            )
            
            (57
            )Other
                income
            
            
            12,133
            
            
            150
            
            
            33,420
            
            
            18,900Total
                Other Income, net
            
            
            11,748
            
            
            12,911
            
            
            29,528
            
            
            44,744**INCOME
                (LOSS) FROM OPERATIONS BEFORE****TAXES
                AND MINORITY INTEREST**
            
            
            449,757
            
            
            (22,468
            )
            
            803,512
            
            
            98,343**INCOME
                TAX EXPENSE**
            
            
            (76,549
            )
            
            (37,726
            )
            
            (133,157
            )
            
            (37,726
            )**MINORITY
                INTEREST**
            
            
            14,494
            
            
            6,207
            
            
            28,475
            
            
            12,694**NET
                INCOME (LOSS)**
            
            
            387,702
            
            
            (53,987
            )
            
            698,830
            
            
            73,311**OTHER
                COMPREHENSIVE INCOME (LOSS)**Foreign
                currency translation gain (loss)
            
            
            127,297
            
            
            (203
            )
            
            153,672
            
            
            97,103**COMPREHENSIVE
                INCOME (LOSS)**
            
            $
            514,999
            
            $
            (54,190
            )
            $
            852,502
            
            $
            170,414**Net
                income (loss) per share -****basic
                and diluted**
            
            $
            0.021
            
            $
            (0.003
            )
            $
            0.038
            
            $
            0.004Weighted
                average number of sharesoutstanding
                during the period -basic
                and diluted
            
            
            18,466,169
            
            
            16,466,169
            
            
            18,466,169
            
            
            16,466,169




The
      accompanying notes are an integral part of these financial
      statements




2





**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC**


**AND
      SUBSIDIARIES**


**UNAUDITED
      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**





For
                the Six
            
            For
                the SixMonths
                Ended
            
            Months
                EndedJune
                30, 2007
            
            June
                30,2006**CASH
                FLOWS FROM OPERATING ACTIVITIES**Net
                income
            
            $
            698,830
            
            $
            73,311Adjusted
                to reconcile net income to net cash providedby
                operating activities:Allowance
                for doubtful accounts - accounts receivable
            
            
            (32,726
            )
            
            -Depreciation
                and amortization - cost of sales
            
            
            148,661
            
            
            110,223Depreciation
                and amortization
            
            
            23,818
            
            
            22,980Minority
                interest
            
            
            (28,475
            )
            
            (12,694
            )Changes
                in operating assets and liabilities(Increase)
                decrease in:Accounts
                receivable
            
            
            (101,614
            )
            
            124,797Inventories
            
            
            (1,191,555
            )
            
            (351,602
            )Due
                from stockholders
            
            
            24,408
            
            
            33,381Other
                assets
            
            
            583,469
            
            
            (40,291
            )Increase
                (decrease) in:Accounts
                payable
            
            
            2,003
            
            
            (19,555
            )Other
                payables and accrued expenses
            
            
            89,903
            
            
            70,117Income
                tax and other taxes payable
            
            
            36,664
            
            
            38,419Due
                to stockholders
            
            
            -
            
            
            (1,250
            )Net
                cash provided by operating activities
            
            
            253,386
            
            
            47,836**CASH
                FLOWS FROM INVESTING ACTIVITIES**Decrease
                in notes receivable
            
            
            258,733
            
            
            -Purchase
                of property and equipment
            
            
            (264,978
            )
            
            (114,391
            )Net
                cash used in investing activities
            
            
            (6,245
            )
            
            (114,391
            )**CASH
                FLOWS FROM FINANCING ACTIVITIES**Net
                cash provided by financing activities
            
            
            -
            
            
            -**EFFECT
                OF EXCHANGE RATES ON CASH**
            
            
            15,822
            
            
            21,363**NET
                INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS**
            
            
            262,963
            
            
            (45,192
            )**CASH
                AND CASH EQUIVALENTS AT BEGINNING OF PERIOD**
            
            
            463,468
            
            
            89,108**CASH
                AND CASH EQUIVALENTS AT END OF PERIOD**
            
            $
            726,431
            
            $
            43,916**SUPPLEMENTAL
                DISCLOSURE OF CASH FLOW INFORMATION**Cash
                paid during the year for:Income
                taxes
            
            $
            914
            
            $
            -Interest
                expenses
            
            $
            15,108
            
            $
            57





The
      accompanying notes are an integral part of these financial
      statements




3





**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC.**


**AND
      SUBSIDIARIES**


**NOTES
      TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**AS
      OF JUNE 30, 2007**





**NOTE
      1**  **ORGANIZATION
      AND BASIS OF PRESENTATION**





Huifeng
      Bio-Pharmaceutical Technology, Inc (“Huifeng Bio-Pharmaceutical”) is a US listed
      company which was incorporated in Nevada on March 16, 2000 under the name
      Enternet, Inc. On May 23, 2002, the Articles of Incorporation were amended
      to
      change the name of the Company to Secured Data, Inc. On October 12, 2005, the
      Articles of Incorporation were amended to change the name of the Company to
      Huifeng Bio-Pharmaceutical Technology, Inc.





Northwest
      Bio-Technic Inc. (“Northwest”) was incorporated in the British Virgin Islands
      (“BVI”) on June 25, 2004. Xian Huifeng Biochemistry Group Joint-Stock Company
      Limited (previously Xian Huifeng Biochemistry Joint-Stock Company Limited)
      (“Huifeng Biochemistry”) was incorporated in the People's Republic of China
      (“PRC”) on January 20, 2000 as a company with limited liabilities and was
      restructured as a joint stock company on September 29, 2002 under the laws
      of
      the PRC. On April 20, 2005, the Articles of Incorporation were amended to change
      the name to Xian Huifeng Biochemistry Group Joint-Stock Company
      Limited.





Huifeng
      Biochemistry produces plant extracts and bio-chemical products used as
      pharmaceutical raw materials in the PRC. Most of its products are distributed
      within the PRC and some European countries.





On
      August
      23, 2001, Huifeng Biochemistry established 70% ownership in a subsidiary, Xian
      Huifeng Biochemistry Engineering Company Limited (“Huifeng Engineering”) in the
      PRC with a registered capital of $265,778. The subsidiary has had no operations
      since its incorporation.





On
      June
      16, 2004 Huifeng Biochemistry acquired an 86.7% interest in Baoji Jisen
      Pharmaceutical Company Limited, later renamed to Xian Huifeng Pharmaceutical
      Company Limited (“Huifeng Pharmaceutical”), a limited liability company in the
      PRC. On November 10, 2004 Huifeng Pharmaceutical increased its registered
      capital from $181,159 to $603,865. The increased registered capital was fully
      subscribed by a stockholder of the Company, diluting the Company's interest
      in
      Huifeng Pharmaceutical from 86.7% to 26%. On May 27, 2005 the PRC Government
      approved Huifeng Biochemistry's increased investment in Huifeng Pharmaceutical
      from $31,401 to $1,685,990 through an increase in the registered capital of
      Huifeng Pharmaceutical from $603,865 to $2,258,454. The acquisition of Huifeng
      Pharmaceutical by Huifeng Biochemistry was accomplished by increasing Huifeng
      Biochemistry's interest in Huifeng Pharmaceutical from 26% to
      80.2%.




4




**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC**


**AND
      SUBSIDIARIES**


**NOTES
      TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**AS
      OF JUNE 30, 2007**




**NOTE
      1**  **ORGANIZATION
      AND BASIS OF PRESENTATION (CONTINUED)**





The
      accompanying unaudited condensed consolidated financial statements have been
      prepared in accordance with accounting principles generally accepted in the
      United States of America for interim financial information and pursuant to
      the
      rules and regulations of the Securities and Exchange Commission. Accordingly,
      they do not include all of the information and footnotes required by generally
      accepted accounting principles for complete financial statements.





It
      the
      opinion of management, the unaudited condensed consolidated financial statements
      contain all adjustments consisting only of normal recurring accruals considered
      necessary to present fairly the Company's consolidated financial position at
      June 30, 2007, the consolidated results of operations for the three and six
      months ended June 30, 2007 and 2006, and consolidated cash flows for the six
      months ended June 30, 2007 and 2006. The consolidated results for the three
      and
      six months ended June 30, 2007 are not necessarily indicative of the results
      to
      be expected for the entire fiscal year ending December 31, 2007. These
      consolidated financial statements should be read in conjunction with the
      consolidated financial statements and notes for the year ended December 31,
      2006
      appearing in the Company's annual report on Form 10-KSB as filed with the
      Securities and Exchange Commission.





**NOTE
      2**  **USE
      OF ESTIMATES**





In
      preparing financial statements in conformity with generally accepted accounting
      principles, management is required to make estimates and assumptions that affect
      the reported amounts of assets and liabilities and the disclosure of contingent
      assets and liabilities at the date of the financial statements and revenues
      and
      expenses during the reported period. Actual results could differ from those
      estimates.





**NOTE
      3**  **PRINCIPLES
      OF CONSOLIDATION**





The
      accompanying unaudited condensed consolidated financial statements as of June
      30, 2007 and 2006 include the financial statements of Huifeng Bio-Pharmaceutical
      and its 100% owned subsidiary Northwest, 100% owned subsidiary Huifeng
      Biochemistry, 70% owned subsidiary Huifeng Engineering and 80.2% owned
      subsidiary Huifeng Pharmaceutical. Minority interests represent the minority
      stockholders’ proportionate share of the profits of Huifeng Engineering and
      Huifeng Pharmaceutical.





All
      significant inter-company balances and transactions have been eliminated in
      consolidation.





**NOTE
      4**  **CASH
      AND CASH EQUIVALENTS**





For
      purposes of the cash flow statements, the Company considers all highly liquid
      investments with original maturities of three months or less at the time of
      purchase to be cash equivalents.




5





**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC**


**AND
      SUBSIDIARIES**


**NOTES
      TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**AS
      OF JUNE 30, 2007**




**NOTE
      5**  **INCOME
      TAXES**





The
      Company accounts for income taxes under the Statement of Financial Accounting
      Standards No. 109, “Accounting for Income Taxes”(“Statement 109”). Under
      Statement 109, deferred tax assets and liabilities are recognized for the future
      tax consequences attributable to differences between the financial statement
      carrying amounts of existing assets and liabilities and their respective tax
      bases. Deferred tax assets and liabilities are measured using enacted tax rates
      expected to apply to taxable income in the years in which those temporary
      differences are expected to be recovered or settled. Under Statement 109, the
      effect on deferred tax assets and liabilities of a change in tax rates is
      recognized in income in the period that includes the enactment date. Huifeng
      Bio-pharmaceutical was incorporated in the United States and has incurred net
      operating loss as for income tax purposes for the six months ended June 30,
      2007
      and 2006.





Northwest,
      a wholly owned subsidiary of the Company, was incorporated in the British Virgin
      Islands and, under current law of the British Virgin Islands, is not subject
      to
      tax on income or on capital gains.





Huifeng
      Biochemistry, a wholly owned subsidiary of Northwest, was incorporated in the
      PRC, registered as a new and high technology enterprise, and is entitled to
      an
      income tax reduction. According to the document of reductions approved by the
      local tax bureau, the income tax rate was reduced from 33% to 15% on a permanent
      basis. Provision for income tax expenses for the six months ended June 30,
      2007
      and 2006 were $131,941 and $37,726 respectively.





Huifeng
      Engineering, a 70% owned subsidiary of Huifeng Biochemistry, was incorporated
      in
      the PRC and subject to PRC income tax which is computed according to the
      relevant laws and regulations in the PRC. No provision for income tax expenses
      for the six months ended June 30, 2007 and 2006 as Huifeng Engineering has
      incurred net operating loss.





Huifeng
      Pharmaceutical, a 80.2% owned subsidiary of Huifeng Biochemistry, was also
      incorporated in the PRC and subject to PRC income tax which is computed
      according to the relevant laws and regulations in the PRC. Provision for income
      tax expenses for the six months ended June 30, 2007 and 2006 were $1,216 and
      $0
      repsectively.





**NOTE
      6**  **EARNINGS
      (LOSS) PER SHARE**





Basic
      and
      diluted net income (loss) per common share is computed based upon the weighted
      average common shares outstanding as defined by Financial Accounting Standards
      No. 128, “Earnings per Share.” As of June 30, 2007 and 2006, there were no
      common share equivalents outstanding with an anti-dilutive effect and not
      included in the calculation of dilutive income per share.





**NOTE
      7**  **BUSINESS
      SEGMENTS**





The
      Company operates in one segment and therefore segment information is not
      presented.





**NOTE
      8**  **RECENT
      ACCOUNTING PRONOUNCEMENTS**





In
      July 2006, the FASB issued FASB Interpretation No. 48, Accounting for
      Uncertainty in Income Taxes—an Interpretation of FASB Statement 109 (“FIN 48”),
      which clarifies the accounting for uncertainty in tax positions. This
      Interpretation provides that the tax effects from an uncertain tax position
      can
      be recognized in the Company’s financial statements, only if the position is
      more likely than not of being sustained on audit, based on the technical merits
      of the position. The provisions of FIN 48 are effective as of the beginning
      of
      fiscal 2007, with the cumulative effect of the change in accounting principle
      recorded as an adjustment to opening retained earnings. The Company is currently
      evaluating the impact this new Standard, but believes that it will not have
      a
      material impact on the Company’s financial position.





In
      September 2006, FASB issued Statement 157, Fair Value Measurements. This
      statement defines fair value and establishes a framework for measuring fair
      value in generally accepted accounting principles (GAAP). More precisely, this
      statement sets forth a standard definition of fair value as it applies to assets
      or liabilities, the principal market (or most advantageous market) for
      determining fair value (price), the market participants, inputs and the
      application of the derived fair value to those assets and liabilities. The
      effective date of this pronouncement is for all full fiscal and interim periods
      beginning after November 15, 2007. The Company is currently evaluating the
      impact this new Standard, but believes that it will not have a material impact
      on the Company’s financial position.




6





**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC**


**AND
      SUBSIDIARIES**


**NOTES
      TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**AS
      OF JUNE 30, 2007**




**NOTE
      8**  **RECENT
      ACCOUNTING PRONOUNCEMENTS (CONTINUED)**





In
      February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for
      Financial Assets and Financial Liabilities” (SFAS 159) which permits entities to
      choose to measure many financial instruments and certain other items at fair
      value that are not currently required to be measured at fair value. SFAS 159
      will become effective for us on January 1, 2008. The Company is currently
      evaluating the impact this new Standard, but believes that it will not have
      that
      it will not have a material impact on the Company’s financial
      position.





**NOTE
      9 NOTES RECEIVABLE**





Notes
      receivable as of June 30, 2007 consisted of the following:





Note
                receivable from a third party, interest rate of 12% per annum,
                non-secured, due September 2007
            
            $
            192,949Current
                maturities
            
            $
            192,949




**NOTE
      10**  **COMMITMENTS
      AND CONTINGENCIES**





**Commitments**




The
      Company occupies office storage spaces owned by third parties under operating
      leases which expire on March 31, 2008 and November 10, 2007 at a quarterly
      rental of $2,652 and $373 respectively. Accordingly, for the six months ended
      June 30, 2007 and 2006, the Company recognized rental expenses for these spaces
      in the amount of $6,050 and $6,376 respectively.





As
      of
      June 30, 2007, the Company has outstanding commitments with respect to the
      non-cancelable operating leasesof $8,494, which are due by June 30,
      2008.





**NOTE
      11**  **RELATED
      PARTY TRANSACTIONS**





As
      of
      June 30, 2007 and 2006, the stockholders owed the Company $0 and $66,690
      respectively for advances made on an unsecured basis and repayable on demand.
      Interest is charged at 6% per annum on the amount due. Total interest income
      amounted to $0 and $1,986 for the six months ended June 30, 2007 and 2006
      respectively.




**NOTE
      12**  **CONCENTRATIONS
      AND RISKS**





During
      the six months ended June 30, 2007 and 2006, 100% of the Company's assets were
      located in China.





During
      the six months ended June 30, 2007 and 2006, 52% and 63% of the Company's
      revenues were derived from companies located in China respectively.





The
      Company relied on three suppliers for approximately $531,922, $463,807 and
      $320,809, representing in aggregate 88% of purchases for the six months ended
      June 30, 2007. Accounts payable to those suppliers as of June 30, 2007 were
      $8,485.




7




**Item
      2. Management's Discussion and Analysis or Plan of
      Operation.**





This
      report contains forward-looking statements within the meaning of the federal
      securities laws. These include statements about our expectations, beliefs,
      intentions or strategies for the future, which we indicate by words or phrases
      such as "anticipate," "expect," "intend," "plan," "will," "we believe," "HFGB
      believes," "management believes" and similar language. The forward-looking
      statements are based on the current expectations of HFGB and are subject to
      certain risks, uncertainties and assumptions, including those set forth in
      the
      discussion under "Management's Discussion and Analysis or Plan of Operation".
      The actual results may differ materially from results anticipated in these
      forward-looking statements. We base the forward-looking statements on
      information currently available to us, and we assume no obligation to update
      them.




On
      December 20, 2004, pursuant to an Agreement with Art Malone, Jr. ("Selling
      Shareholder"), the Selling Shareholder sold 7,229,601 shares of the common
      stock
      of the Company for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin,
      individuals on the closing date of December 20, 2004. Such 7,229,601 shares
      of
      the common stock of the Company represented approximately 56.18% of the total
      outstanding stock of the Company as of that date.




Immediately
      thereafter, pursuant to the terms of an Agreement and Plan of Reorganization
      dated December 20, 2004 ("Northwest Agreement"), the Company agreed to purchase
      all of the outstanding shares of Northwest BioTechnic, Inc. (“Northwest”), a
      British Virgin Islands corporation (the “Acquisition”). Northwest was
      incorporated in the British Virgin Islands on June 25, 2004.




At
      the
      time of the Acquisition, Northwest had a total of 500,000 shares issued and
      outstanding, 250,000 of which were held by Jing An Wang, and 50,000 each were
      held by Xinwen Hou, Zhang Jungi, Wang Bijun, Wang Zhilan, and Wang Xugang (the
      “Northwest Shareholders”. Pursuant to the terms of the Northwest Agreement, at
      the closing of the Acquisition, the Company delivered the following
      consideration to the Northwest Shareholders: (i) 80,735,590 newly-issued shares
      of the common stock of the Company (the “Initial Northwest Consideration”) in
      exchange for 30% of the total outstanding shares of Northwest (such shares
      of
      the common stock of the Company allocated among the Northwest Shareholders
      on a
      pro rata basis according to their respective ownership of Northwest); and (ii)
      a
      promissory note (the “Promissory Note”) payable to the Northwest Shareholders
      for the total amount of $1,900,000, in exchange for the remaining 70% of the
      total outstanding shares of Northwest. The Promissory Note was convertible
      into
      10,465,725 shares of the Company's common stock (allocated among the Northwest
      Shareholders on a pro rata basis according to their respective ownership of
      Northwest), with such number of shares calculated assuming the completion of
      a
      one-for-eighteen reverse split of the Company's common stock prior to such
      conversion. Based on the current ownership of Northwest shares by the Northwest
      Shareholders, Jing An Wang would receive 5,232,860 shares of the Company's
      common stock upon conversion, and each of Xinwen Hou, Zhang Jungi, Wang Bijun,
      Wang Zhilan, and Wang Xugang would receive 1,046,573 shares of the Company's
      common stock. On October 12, 2005, the Company issued 10,465,725 shares of
      restricted common stock in conversion of the Convertible Promissory Note of
      $1,900,000.




Northwest
      operates through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock
      Company ("Huifeng"), which is a joint venture company established under the
      laws
      of China and is engaged in the production and sales of plant extracts,
      biochemical products and pharmaceutical raw products in the PRC.




The
      exchange was treated as a reverse acquisition for accounting purposes. As such,
      the financial information reflected activity subsequent to the acquisition
      of
      the Company and its subsidiaries and financial activity of Northwest prior
      to
      the acquisition. We will continue the business operations conducted by
      Northwest.




The
      Company filed a definitive Information Statement pursuant to Section 14(c)
      of
      the Securities Exchange Act of 1934 on September 13, 2005, to change the name
      of
      the Company to "Huifeng Bio-Pharmaceutical Technology, Inc". On October 12,
      2005, the name of the Company changed to Huifeng Bio-pharmaceutical Technology,
      Inc and the ticker symbol changed to HFGB.OB.




8




**CRITICAL
      ACCOUNTING POLICIES AND ESTIMATES**




We
      have
      identified one policy area as critical to the understanding of our consolidated
      financial statements. The preparation of our consolidated financial statements
      requires management to make estimates and assumptions that affect the reported
      amounts of assets and liabilities and disclosure of contingent assets and
      liabilities at the date of the consolidated financial statements and the
      reported amounts of sales and expenses during the reporting periods. With
      respect to net realizable value of the Company's accounts receivable and
      inventories, significant estimation judgments are made and actual results could
      differ materially from these estimates.





The
      Company does not have any reserves against its accounts receivable or
      inventories at June 30, 2007 and 2006. Management's estimation that there are
      no
      reserves is based on the current facts that there is no significant aged
      accounts receivable and the current inventory turnover is sufficient to realize
      the current carrying value of the inventories. In making their judgment,
      management has assumed that there will be continued demand for their products
      in
      the future, thereby maintaining adequate turnover of the inventories.
      Additionally, management has assumed that customers will continue to pay their
      outstanding invoices timely, and that their customers' financial positions
      will
      not deteriorate significantly in the future, which would result in their
      inability to pay their debts to the Company. While the Company's management
      currently believes that there is little likelihood that the actual results
      of
      their current estimates will differ materially from its current estimates,
      if
      customer demand for its products decreases significantly in the near future,
      or
      if the financial position of its customers deteriorates in the near future,
      the
      Company could realize significant write downs for slow moving inventories or
      non-recoverable accounts receivable.




We
      believe the following is among the most critical accounting policies that affect
      our consolidated financial statements. We suggest that our significant
      accounting policies, as described in our consolidated financial statements
      in
      the Summary of Significant Accounting Policies, be read in conjunction with
      this
      Management's Discussion and Analysis of Financial Condition and Results of
      Operations.





We
      recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No.
      104.
      All of the following criteria must exist in order for us to recognize
      revenue:





1.
      Persuasive evidence of an arrangement exists;





2.
      Delivery has occurred or services have been rendered;





3.
      The
      seller's price to the buyer is fixed or determinable; and





4.
      Collectibility is reasonably assured.





The
      majority of the Company's revenue results from sales contracts with
      distributors, and revenue is generated upon the shipment of goods. The Company's
      pricing structure is fixed and there are no rebate or discount programs.
      Management conducts credit background checks for new customers as a means to
      reduce the subjectivity of assuring collectibility. Based on these factors,
      the
      Company believes that it can apply the provisions of SAB 104 with minimal
      subjectivity.





**RESULTS
      OF OPERATIONS**





THREE
      MONTHS ENDED JUNE 30, 2007 COMPARED TO THREE MONTHS ENDED JUNE 30,
      2006





Revenues,
      Cost of Revenues and Gross Margin





Revenues
      for the quarter ended June 30, 2007 were $1,610,478, an increase of $1,151,230
      from $459,248 for the same quarter in 2006. Our increase in revenues for the
      second quarter of 2007 was mainly due to the significant increase in our export
      and domestic sales, which were included our products of NF11 Rutin, L-Rhamnose,
      Quercetin, Troxerutin (injection) and Diosmin in the three months ended June
      30,
      2007 approximately $887,819 compared to the three months ended June 30, 2006
      as
      a result of our increase in sales of pharmaceutical intermediates and
      pharmaceutical material products as follows:




For
                the quarter ended
              June
                30,
            
            Increase
                /Product
            
            2007
            
            2006
            
            (Decrease)Pharmaceutical
                intermediates
            
            $
            654,399
            
            $
            101,609
            
            $
            552,790Pharmaceutical
                material
            
            
            847,813
            
            
            250,198
            
            
            597,615Plant
                Extractive and others
            
            
            108,266
            
            
            107,441
            
            
            825TOTAL
            
            $
            1,610,478
            
            $
            459,248
            
            $
            1,151,230




Cost
      of
      revenues for the quarter ended June 30, 2007 were $1,042,071, an increase of
      $684,230 from $357,841 for the quarter ended June 30, 2006. Compared to the
      quarter ended June 30, 2006, the increase in the cost of revenues for the second
      quarter of 2007 was caused by the significant increase in sales of our
      pharmaceutical material and Pharmaceutical intermediates products as
      follows:




For
                the quarter ended
              June
                30,
            
            Increase
                /Product
            
            2007
            
            2006
            
            (Decrease)Pharmaceutical
                intermediates
            
            $
            401,607
            
            $
            68,944
            
            $
            332,663Pharmaceutical
                material
            
            
            552,920
            
            
            198,538
            
            
            354,382Plant
                Extractive and others
            
            
            87,544
            
            
            90,359
            
            
            (2,815
            )TOTAL
            
            $
            1,042,071
            
            $
            357,841
            
            $
            684,230




9




Gross
      margin for the quarter ended June 30, 2007 was $568,407, an increase of $467,000
      from $101,407 for the same period ended June 30, 2006.





Our
      gross
      profit margin for 2007 increased from 22.1% for the second quarter of 2006
      to
      35.3% in the same quarter in 2007 because of the lower unit cost of our products
      and better profit margin of both domestic and export sales.





General
      and Administrative Expenses





General
      and Administrative expenses totaled $93,764 for the three months ended June
      30,
      2007, an increase of $17,579 from $76,185 for the three months ended June 30,
      2006. The increase in general and administrative expenses was mainly due to
      an
      increase in consulting fees of $12,937 for application of certificates of Drug
      Master Files (DMF) in respect to our products of Diosmin and Troxerutin and
      foreign exchange loss of $2,614 from export sales incurred during the three
      months ended June 30, 2007 compared to three months ended June
      30,2006.





Selling
      and Distribution Expenses





Selling
      and distribution expenses totaled $24,652 for the three months ended June 30,
      2007, a decrease of $25,162 from $49,814 for the three months ended June 30,
      2006. The decrease in selling and distribution expenses was mainly due to the
      decrease in conference meetings of $6,934 and freight expenses of $13,617 in
      the
      second quarter of 2007 as compared to the same quarter last year.





SIX
      MONTHS ENDED JUNE 30, 2007 COMPARED TO SIX MONTHS ENDED JUNE 30,
      2006





Revenues,
      Cost of Revenues and Gross Margin





Revenues
      for the six months ended June 30, 2007 were $3,008,147, an increase of
      $1,445,452 from $1,562,695 for the same period in 2006. Our increase in revenues
      for the six months ended June 30, 2007 was mainly due to the significant
      increase in our export and domestic sales, which were included our products
      of
      L-Rhamnose, Quercetin, Troxerutin (injection) and Diosmin for the six months
      ended June 30, 2007 approximately $1,379,006 compared to the six months ended
      June 30, 2006 as a result of our increase in sales of pharmaceutical material
      and pharmaceutical intermediates products as follows:




Six
                months ended
              June
                30,
            
            Increase
                /Product
            
            2007
            
            2006
            
            (Decrease)Pharmaceutical
                intermediates
            
            $
            1,255,450
            
            $
            515,761
            
            $
            739,689Pharmaceutical
                material
            
            
            1,559,024
            
            
            893,169
            
            
            665,855Plant
                Extractive and others
            
            
            193,673
            
            
            153,765
            
            
            39,908TOTAL
            
            $
            3,008,147
            
            $
            1,562,695
            
            $
            1,445,452





Cost
      of
      revenues for the six months ended June 30, 2007 were $2,031,889, an increase
      of
      $740,338 from $1,291,551 for the six months ended June 30, 2006. Compared to
      the
      six months ended June 30, 2006, the increase in the cost of revenues for the
      six
      months ended June 30, 2007 was caused by the significant increase of sales
      of
      our pharmaceutical material pharmaceutical intermediates products as
      follows:




Six
                months ended
              June
                30,
            
            Increase
                /Product
            
            2007
            
            2006
            
            (Decrease)Pharmaceutical
                intermediates
            
            $
            798,738
            
            $
            403,038
            
            $
            395,700Pharmaceutical
                material
            
            
            1,062,325
            
            
            766,966
            
            
            295,359Plant
                Extractive and others
            
            
            170,826
            
            
            121,547
            
            
            49,279TOTAL
            
            $
            2,031,889
            
            $
            1,291,551
            
            $
            740,338




10





Gross
      margin for the six months ended June 30, 2007 was $976,258, an increase of
      $705,114 from $271,144 for the period ended June 30, 2006.





Our
      gross
      profit margin for 2007 increased from 17.3% in the first six months of 2006
      to
      32.5% in the same period in 2007. Because of the lower unit cost of our products
      and better profit margin of both domestic and export sales.





General
      and Administrative Expenses





General
      and Administrative expenses totaled $134,760 for the six months ended June
      30,
      2007, an increase of $24,641 from $110,119 for the six months ended June 30,
      2006. The increase in general and administrative expenses was mainly due to
      an
      increase in consulting fees of $12,937 for application of certificates of Drug
      Master Files (DMF) in respect to our products of Diosmin and Troxerutin, foreign
      exchange loss of $5,713 from export sales incurred and traveling expenses of
      $4,543 for financial conferences in Beijing and Tianjin during the six months
      ended June 30, 2007 compared to the six months ended June 30,
      2006.





Selling
      and Distribution Expenses





Selling
      and distribution expenses totaled $43,696 for the six months ended June 30,
      2007, a decrease of $40,749 from $84,445 for the six months ended June 30,
      2006.
      The decrease in selling and distribution expenses was mainly due to the decrease
      in the conference meetings of $12,558 and freight expenses of $16,395 during
      the
      first six months of 2007 compared with the same period of 2006.





Liquidity
      and Capital Resources





Cash





Our
      cash
      balance amounted to $726,431 at June 30, 2007.





In
      the
      six months ended June 30, 2007, our cash provided by operating activities
      totaled $253,386, mainly due to our net income for the period of $698,830 and
      a
      decrease in other assets of $583,469. In the six months ended June 30, 2007,
      cash flow used in investing activities totaled $6,245.





The
      Company is currently funding its operations from our income from
      operations.





Working
      Capital





Our
      working capital amounted to $3,556,043 at June 30, 2007.





**INFLATION**





Inflation
      has not had a material impact on our business.





**CURRENCY
      EXCHANGE FLUCTUATIONS**





All
      of
      our revenues and the majority of our expenses for the six months ended June
      30,
      2007 were denominated primarily in Renminbi ("RMB"), the currency of China,
      and
      were converted into US dollars at the exchange rate of 7.6248 to 1. Since July
      22, 2005, the Renminbi has strengthened against the US dollars. As a result
      of
      the appreciation of RMB, we recognized a foreign currency translation gain
      of
      $153,672 during the first six months of 2007. There could be no assurance that
      RMB-to-U.S. dollar exchange rates will remain stable. A devaluation of RMB
      relative to the U.S. dollar would adversely affect our business, financial
      condition and results of operations. We do not engage in currency
      hedging.





**Item
      3. Controls and Procedures**





We
      maintain disclosure controls and procedures that are designed to ensure that
      information required to be disclosed in the Company's Exchange Act reports
      is
      recorded, processed, summarized and reported within the time periods specified
      in the SEC's rules and forms, and that such information is accumulated and
      communicated to our management, including its Chief Executive Officer and Chief
      Financial Officer, as appropriate, to allow timely decisions regarding required
      disclosure based closely on the definition of "disclosure controls and
      procedures" in Rule 13a-14(c). Our disclosure controls and procedures are
      designed to provide a reasonable level of assurance of reaching our desired
      disclosure control objectives. In designing and evaluating the disclosure
      controls and procedures, our management recognized that any controls and
      procedures, no matter how well designed and operated, can provide only
      reasonable assurance of achieving the desired control objectives, and management
      necessarily was required to apply its judgment in evaluating the cost-benefit
      relationship of possible controls and procedures. Our certifying officers have
      concluded that our disclosure controls and procedures are effective in reaching
      that level of assurance.




As
      of the
      end of the period of this report, we carried out an evaluation, under the
      supervision and with the participation of our management including our Chief
      Executive Officer and our Chief Financial Officer, of the effectiveness of
      the
      design and operation of our disclosure controls and procedures. Based on the
      foregoing, our Chief Executive Officer and Chief Financial Officer concluded
      that our disclosure controls and procedures were effective. We have put
      additional controls and procedures in place to assure that we attain the
      appropriate level of assurance on a going forward basis.




11





**PART
      II. OTHER INFORMATION**





**Item
      1. Legal Proceedings:**





We
      are
      currently not involved in any litigation that we believe could have a material
      adverse effect on our financial condition or results of operations. There is
      no
      action, suit, proceeding, inquiry or investigation before or by any court,
      public board, government agency, self-regulatory organization or body pending
      or, to the knowledge of the executive officers of our Company or any of our
      subsidiaries, threatened against or affecting the Company, our common stock,
      any
      of our subsidiaries or of our Company's or our Company's subsidiaries' officers
      or directors in their capacities as such, in which an adverse decision could
      have a material adverse effect.





**Item
      2 - Unregistered Sales of Equity Securities and Use of
      Proceeds:**





None





**Item
      3. Defaults Upon Senior Securities:**





None





**Item
      4. Submission of Matters to a Vote of Security Holders:**





None





**Item
      5. Other Information:**





None





**Item
      6. Exhibits and Reports on Form 8-K**





(a)
      Exhibits





31.1
            
            Sarbanes
                Oxley Section 302 Certification31.2
            
            Sarbanes
                Oxley Section 302 Certification32.1
            
            Sarbanes
                Oxley Section 906 Certification32.2
            
            Sarbanes
                Oxley Section 906 Certification





12




SIGNATURES





Pursuant
      to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
      1934, as amended, the registrant has duly caused this Report to be signed on
      its
      behalf by the undersigned, thereunto duly authorized this 14th day of August,
      2007.


HUIFENG
                BIO-PHARMACEUTICAL TECHNOLOGY, INC.By:
            /s/ Jing
                An WangJing
                An Wang
              Chief
                Executive Officer




13